Search form
Search
contact us
Navigation
home
boards
job center
job ratings
cp wire
device news
pharmagather
catering
advertise
Legal Help
login/register
You are here
Home
»
companies
» FTC
FTC
Surprise: AstraZeneca's $39B Alexion buy clears a newly vigilant FTC without a hitch
Surprise: AstraZeneca's $39B Alexion buy clears a newly vigilant FTC without a hitch
Fierce Pharma
AstraZeneca
Alexion
M&A
FTC
Flag link:
An antitrust expert weighs in on the FTC’s complaint against Illumina
An antitrust expert weighs in on the FTC’s complaint against Illumina
Stat
Illumina
Grail
M&A
antitrust
FTC
Flag link:
Illumina Stock Tumbles As FTC Moves To Block $7.1 Billion Grail Acquisition
Illumina Stock Tumbles As FTC Moves To Block $7.1 Billion Grail Acquisition
Investors Business Daily
Illumina
FTC
Grail
M&A
liquid biopsy
Flag link:
FTC eyes new approach to pharmaceutical mergers
FTC eyes new approach to pharmaceutical mergers
The Hill
FTC
M&A
Flag link:
Antitrust Panel Sets Sights on Big Pharma for Next Target
Antitrust Panel Sets Sights on Big Pharma for Next Target
BioSpace
Big Pharma
antitrust
FTC
M&A
Flag link:
With FTC Nod, Stryker is Set to Close Wright Medical Deal
With FTC Nod, Stryker is Set to Close Wright Medical Deal
Medical Devices and Diagnostics Industry
devices
Stryker
Wright Medical
M&A
FTC
UK
Flag link:
Date Is Set for Merger Between Mylan and Pfizer's Upjohn Unit
Date Is Set for Merger Between Mylan and Pfizer's Upjohn Unit
Motley Fool
M&A
FTC
Pfizer
Upjohn
Mylan
generics
Flag link:
Federal judge denies Martin Shkreli all but one motion to dismiss monopoly claims in the FTC's Daraprim lawsuit
Federal judge denies Martin Shkreli all but one motion to dismiss monopoly claims in the FTC's Daraprim lawsuit
Endpoints
Martin Shkreli
FTC
Vyera Pharmaceuticals
Daraprim
drug pricing
Flag link:
Martin Shkreli continued to orchestrate anti-competitive schemes for Daraprim behind bars — FTC
Martin Shkreli continued to orchestrate anti-competitive schemes for Daraprim behind bars — FTC
Endpoints
Martin Shkreli
Daraprim
FTC
generics
Flag link:
Abbvie-Allergan complete, but critics continue to raise anti-competitive concerns
Abbvie-Allergan complete, but critics continue to raise anti-competitive concerns
Endpoints
AbbVie
Allergan
M&A
FTC
Flag link:
AbbVie, Allergan score FTC approval for $63B merger with one final hurdle left to go
AbbVie, Allergan score FTC approval for $63B merger with one final hurdle left to go
Fierce Pharma
AbbVie
Allergan
M&A
FTC
Flag link:
AbbVie and Allergan Sign Divestiture Consent Decree with FTC, Move Closer to Finalizing Merger
AbbVie and Allergan Sign Divestiture Consent Decree with FTC, Move Closer to Finalizing Merger
BioSpace
AbbVie
Allergan
FTC
M&A
Flag link:
AbbVie, Allergan merger may face regulatory delay due to COVID-19: report
AbbVie, Allergan merger may face regulatory delay due to COVID-19: report
Fierce Pharma
AbbVie
Allergan
FTC
M&A
COVID-19
Flag link:
The FDA and FTC Announce an Effort to Deter Anti-Competitive Practices Among Drugmakers
The FDA and FTC Announce an Effort to Deter Anti-Competitive Practices Among Drugmakers
Motley Fool
FDA
FTC
drug pricing
anti-competitive scheme
biosimilars
Flag link:
Martin Shkreli is sued by the FTC and NY attorney general for illegally cornering a market
Martin Shkreli is sued by the FTC and NY attorney general for illegally cornering a market
Stat
Martin Shkreli
FTC
New York
Vyera Pharmaceuticals
Daraprim
Flag link:
Roche's $4.8B deal for Spark cleared by FTC after long delay
Roche's $4.8B deal for Spark cleared by FTC after long delay
Biopharma Dive
Roche
Spark Therapeutics
M&A
FTC
Flag link:
82 Professors Call on Court to Support FTC Decision in Pay-for-Delay Case
82 Professors Call on Court to Support FTC Decision in Pay-for-Delay Case
RAPS.org
FTC
pay-for-delay
Endo Pharmaceuticals
generics
Flag link:
After big M&A year, will pharma move away from massive deals in 2020?
After big M&A year, will pharma move away from massive deals in 2020?
Fierce Pharma
M&A
Sanofi
Merck
AbbVie
Allergan
Bristol-Myers Squibb
Celgene
FTC
Flag link:
Disruptor of the Year: The Federal Trade Commission
Disruptor of the Year: The Federal Trade Commission
Biopharma Dive
FTC
M&A
Roche
Spark Therapeutics
Flag link:
Bristol-Celgene Merger Leaps FTC Clearance; Deal Set To Close Wednesday
Bristol-Celgene Merger Leaps FTC Clearance; Deal Set To Close Wednesday
Investors Business Daily
Bristol-Myers Squibb
Celgene
FTC
M&A
Flag link:
Pages
1
2
3
4
5
6
7
next ›
last »